|
The Nanoscale Science, Engineering, and Technology (NSET) Subcommittee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, ATSDR
|
NCI, OD/OSP
|
This subcommittee of the National Science and Technology Council's Committee on Technology is responsible for coordinating the National Nanotechnology Initiative (NNI). The NNI was established in 2001 to coordinate federal research and development in nanotechnology by providing a vision of the long-term benefits and opportunities offered by nanotechnology and acting as a locus for communication, cooperation, and collaboration between federal agencies involved in nanotechnology research and development. In 2016, the NSET updated its strategic plan to reflect the fact that nanotechnology is now a broadly enabling technology, not simply an area of research at the nanoscale. The new strategic plan outlines four goals: (1) advance a world-class nanotechnology research and development program, (2) foster the transfer of new technologies into products for commercial and public benefit, (3) develop and sustain educational resources, a skilled workforce, and a dynamic infrastructure and toolset to advance nanotechnology, and (4) support responsible development of nanotechnology.
|
|
The National Ending the HIV Epidemic (EHE) Meeting
|
Meeting/ Workshop
|
CDC, HRSA, OASH
|
NIAID, NICHD, NIDA, NIMH, OD/DPCPSI/OAR
|
On September 15, 2022, 350 researchers, government leaders, public health partners, and community members from throughout the U.S. participated in the hybrid "2nd National Meeting for Research and Community Collaboration towards Ending the HIV Epidemic (EHE) in the U.S. Meeting" hosted by the NIH and the UAB CFAR. The meeting featured presentations by academic investigators and their implementation and community partners funded through NIH EHE awards and promoted the sharing of best practices and generalizable findings.
|
|
The NIH Helping to End Addiction Long Term (HEAL) Initiative
|
Research Initiative
|
AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA
|
NIDA, NCATS, NCCIH, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDDK, NIMH, NINDS, OD/OSP, OD/DPCPSI/OBSSR
|
In April 2018, the National Institutes of Health (NIH) launched the HEAL (Helping to End Addiction Long-term) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. This Initiative will build on extensive, well-established NIH research, including basic science of the complex neurological pathways involved in pain and addiction, implementation science to develop and test treatment models, and research to integrate behavioral interventions with medications for opioid use disorder (OUD) The NIH HEAL Initiative will bolster research across NIH to improve treatments for opioid misuse and addiction and enhance pain management. The NIH HEAL Initiative forges collaborations among research programs across NIH, the U.S. Department of Health and Human Services, and the private sector.
|
|
The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL)
|
Research Initiative
|
CDC
|
NIAID
|
The PREVAIL partnership was established between the governments of Liberia and the United States. The Government of Liberia is represented through the Ministry of Health (MOH) and three autonomous agencies, the United States government is represented through NIAID and the Centers for Disease Control (CDC). The purpose of this partnership is to conduct collaborative biomedical and public health research to advance science, strengthen health policy and practice, and improve the health of Liberians and people worldwide while enhancing Liberian preparedness and agility to rapidly respond during any future infectious disease outbreaks.
|
|
The President's Task Force on Environmental Health risks and Safety risks to children; Asthma Disparities working group
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, IHS
|
NHLBI, NIAID, NICHD, NIMHD, NINR
|
Group of federal partners (HHS and non-HHS) working to eliminate disparities in children with asthma
|
|
The Role of the Scavenger Receptor B Family Proteins (SR-BI, SR-BII and CD36) in Infection and Sepsis
|
Research Initiative
|
FDA
|
CC
|
The Role of the Scavenger Receptor B Family Proteins (SR-BI, SR-BII and CD36) in Infection and Sepsis
|
|
The Scientific Registry of Transplant Recipients (SRTR) Visiting Committee
|
Committee, Work group, Advisory group, or Task Force
|
HRSA
|
NIAID
|
The SRTR Visiting Committee advises the SRTR on:(1) analytic methodologies to support the Organ Procurement and Transplantation Network policy development and evaluation; (2) objectives, study designs, and statistical methods for research projects performed by SRTR, including risk-adjusted analyses of organ procurement organization and transplant program performance; (3) methods used in simulated allocation models; (4) new areas of research and innovative advances in analytical methodologies that might improve the effectiveness of SRTR.
|
|
The United States Renal Data System (USRDS)
|
Resource Development
|
CMS, HRSA
|
NIDDK
|
The United States Renal Data System (USRDS), supported and hosted by NIDDK, is a national data system that collects, analyzes, and distributes information about chronic kidney disease and end-stage renal disease (ESRD) in the United States. The missions of USRDS are: (1) To characterize the total renal patient population and describe the distribution of patients by socio-demographic variables across treatment modalities; (2) To report on the incidence, prevalence, mortality rates, and trends over time of renal disease by primary diagnosis, treatment modality and other variables; (3) To develop and analyze data on the effect of various modalities of treatment by disease and patient group categories; (4) To identify problems and opportunities for more focused special studies of renal research issues; (5) To conduct cost effectiveness studies and other economic studies of ESRD; and (6) To make the data available to investigators, and by supporting investigator-initiated projects, to conduct biomedical and economic analyses of ESRD patients.
|
|
Therapies for patients with rare tumors and genetic tumor predisposition
|
Research Initiative
|
FDA
|
NCI
|
Therapies for patients with rare tumors and genetic tumor predisposition
|
|
Tobacco and Nicotine Research Interest Group (TANRIG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, SAMHSA, FDA, CMS
|
OD/DPCPSI/ODP, FIC, NCI, NEI, NHGRI, CSR, NCCIH, NIAMS, NIMH
|
The Tobacco and Nicotine Research Interest Group (TANRIG) was formed in January 2003 with the goal of increasing collaboration, coordination, and communication of tobacco- and nicotine-related research among National Institutes of Health Institutes and Centers, as well as with other relevant US Department of Health and Human Services agencies.
|